

Media Release

Zug, 10 September 2025

## **HBM Portfolio Company Swixx BioPharma and Lundbeck Sign Multi-Regional CNS Partnership**

HBM Healthcare Investments, a leading investor in global healthcare companies, announces that its portfolio company Swixx BioPharma, and its affiliated companies (Swixx) have signed a transformative, multi-regional distribution and services agreement with H. Lundbeck A/S.

Under the agreement, Swixx will distribute and commercialise Lundbeck's entire in-market central nervous system (CNS) portfolio across selected markets in three key regions: South-East Europe (including Israel and Russia), Turkey and Latin America. This multi-regional partnership includes novel and mature therapies for psychiatric and neurological conditions and further establishes Swixx as a major player in the CNS therapeutic area. It also highlights the growing industry trend of outsourcing commercial operations in emerging markets.

The partnership exemplifies Swixx's ability to deliver value through local expertise, operational excellence and strategic vision — an approach that aligns with HBM Healthcare Investments' commitment to supporting outstanding entrepreneurs and innovative ventures.

Privately held Swixx is the largest investment in the HBM portfolio. HBM Healthcare Investments has been a major shareholder since 2017, owning 25.1 percent of the company.

### **Contact**

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or via e-mail at [andreas.wicki@hbmhealthcare.com](mailto:andreas.wicki@hbmhealthcare.com).

### **About Swixx Group**

Swixx Group is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Group of companies and affiliates operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With presence in 46 countries, more than 1,700 employees and sales which exceeded 1.2 billion Euros in 2024, the Group is one of the fastest-growing independent commercialization platforms for biopharma globally. Swixx has gathered outstanding rare disease, oncology-hematology, specialty, vaccines and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com).

## About Lundbeck

Lundbeck is a global biopharmaceutical company dedicated exclusively to brain health. With over 70 years of neuroscience expertise, the company develops transformative treatments for neurological and psychiatric disorders. Lundbeck's research and development efforts focus on complex brain diseases, expanding into neuro-specialty and neuro-rare areas from its strong foundation in psychiatry and neurology. Headquartered in Denmark, Lundbeck employs approximately 5,700 people across more than 50 countries, with products available in over 80 markets.

## About HBM Healthcare Investments

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## Disclaimer

The publication is for information purposes only and does not constitute an offer to sell or a solicitation to buy or subscribe for securities. This news release does not constitute a prospectus within the meaning of Art. 35ff FinSA, or securities prospectus in the sense of the German securities prospectus law. This news release and the information contained therein is not intended for distribution to the United States of America (USA) or within the USA and may not be distributed or forwarded to U.S. persons (including legal persons) or to publications with a general distribution in the USA. This news release is not an offer or solicitation to buy securities in the United States. HBM Healthcare Investments Ltd's securities were not issued in accordance with the U.S. securities laws, and may not be sold, offered for sale, or delivered in the U.S. or to U.S. individuals without prior registration or without a registration exemption. Some information quoted was obtained from external sources HBM considers to be reliable. HBM cannot guarantee the adequacy, accuracy, timeliness or completeness of or be held responsible or liable for errors of fact regarding such data and information obtained from third parties, and this data may change with market conditions. 08/2025